Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Corneal Neovascularization D016510 8 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Helicobacter Infections D016481 21 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
HIV Infections D015658 20 associated lipids
AIDS Dementia Complex D015526 4 associated lipids
Leukemia, Eosinophilic, Acute D015472 3 associated lipids
Leukemia, Myeloid, Acute D015470 19 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Leukemia, T-Cell D015458 23 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Reperfusion Injury D015427 65 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Wounds and Injuries D014947 20 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Viremia D014766 4 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Uremia D014511 33 associated lipids
Tumor Virus Infections D014412 8 associated lipids
Toxemia D014115 3 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Thrombosis D013927 49 associated lipids
Thrombocytosis D013922 4 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombasthenia D013915 4 associated lipids
Thalassemia D013789 8 associated lipids
Tangier Disease D013631 8 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Subacute Sclerosing Panencephalitis D013344 3 associated lipids
Stomatitis D013280 14 associated lipids
Stomach Ulcer D013276 75 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Spasm D013035 5 associated lipids
Sneezing D012912 6 associated lipids
Shock, Traumatic D012774 4 associated lipids
Shock, Septic D012772 11 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Le Blanc K et al. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. 1998 Thromb. Res. pmid:9772010
Eche N et al. Platelet aggregating and procoagulant activities of cultured human breast cancer cells (FAM). 1986 Thromb. Res. pmid:3726808
Powling MJ and Hardisty RM Differential effects of 12-O-tetradecanoylphorbol 13-acetate on platelet responses to various agonists in the presence and absence of extracellular Ca2+. 1986 Thromb. Res. pmid:3787566
Namm DH and High JA Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. 1980 Thromb. Res. pmid:7209881
Hanss M and Dechavanne M 48740 RP, an antagonist of PAF, does not affect human plasma fibrinolysis before and after venous occlusion. 1988 Thromb. Res. pmid:3126559
Okamoto M et al. Platelet activating factor (PAF) involvement in endotoxin-induced thrombocytopenia in rabbits: studies with FR-900452, a specific inhibitor of PAF. 1986 Thromb. Res. pmid:3754990
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Kurose I et al. Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. 1991 Thromb. Res. pmid:1650966
Valone FH Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. 1987 Thromb. Res. pmid:3590086
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. 1987 Thromb. Res. pmid:3590110
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Karlsson H et al. Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. 1998 Thromb. Res. pmid:9694244
Catalán RE et al. Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. 1994 Thromb. Res. pmid:7974386
Nishizawa EE and Della-Coletta AA The formation of a thrombin-like material (TLM) following stimulation of leukocytes. 1984 Thromb. Res. pmid:6484896
Lalau Keraly C et al. Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. 1984 Thromb. Res. pmid:6740569
Bernat A and Herbert JM Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. 1994 Thromb. Res. pmid:8073411
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Kohayakawa M and Inoue K Augmentation of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF)-induced human platelet activation by C-reactive protein. 1986 Thromb. Res. pmid:3083530
Battistini B et al. Endothelin-1 does not affect human platelet aggregation in whole blood and platelet rich plasma. 1990 Thromb. Res. pmid:2278035
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Csáki C et al. Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. 1992 Thromb. Res. pmid:1412179
Inoue Y et al. Effect of a platelet activating factor antagonist and antithrombin III on septicemia and endotoxemia in rats. 1991 Tohoku J. Exp. Med. pmid:2063402
Nishihira J et al. Purification and characterization of the specific binding protein for platelet activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) from human platelets. 1985 Tohoku J. Exp. Med. pmid:3001971
Isobe J and Mizuno A Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets. 1982 Tokushima J. Exp. Med. pmid:7170716
Ezoulin MJ et al. Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. 2006 Toxicol In Vitro pmid:16472967
Baskin SI et al. The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice. 1996 Toxicol. Appl. Pharmacol. pmid:8806852
Wright DT et al. Ozone stimulates release of platelet activating factor and activates phospholipases in guinea pig tracheal epithelial cells in primary culture. 1994 Toxicol. Appl. Pharmacol. pmid:8048050
Nomura DK et al. Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. 2008 Toxicol. Appl. Pharmacol. pmid:18164358
Samet JM and Friedman M Effect of ozone on platelet activating factor metabolism in phorbol-differentiated HL60 cells. 1992 Toxicol. Appl. Pharmacol. pmid:1440609
Hanslik T et al. Effect of the platelet activating factor antagonist BN52021 in rabbits: role in gentamicin nephrotoxicity. 1994 Toxicol. Appl. Pharmacol. pmid:8079343
Ramos G et al. Platelet activating factor receptor binding plays a critical role in jet fuel-induced immune suppression. 2004 Toxicol. Appl. Pharmacol. pmid:15020195
Feuerstein G et al. Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis. 1987 Toxicol. Lett. pmid:3660430
Bailie MB et al. Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity. 1996 Toxicol. Lett. pmid:8614909
Mahgoub AA Thymoquinone protects against experimental colitis in rats. 2003 Toxicol. Lett. pmid:12749817
Flaherty MM et al. Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. 2012 Toxicol. Sci. pmid:22025730
Grandoni KM et al. Trichothecene mycotoxins inhibit phosphoinositide hydrolysis in bovine platelets stimulated with platelet activating factor. 1992 Toxicology pmid:1311467
Pearson JM et al. Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. 1997 Toxicology pmid:9231696
Gambero A et al. Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2. 2004 Toxicon pmid:15450921
Teixeira CF et al. Hyperalgesia induced by Bothrops jararaca venom in rats: role of eicosanoids and platelet activating factor (PAF). 1994 Toxicon pmid:8052996
Shiroma N et al. Haemodynamic and haematologic effects of Acanthaster planci venom in dogs. 1994 Toxicon pmid:7846692
Havt A et al. The renal effects of Bothrops jararacussu venom and the role of PLA(2) and PAF blockers. 2001 Toxicon pmid:11600146
Castro-Faria-Neto HC et al. Pro-inflammatory activity of enterolobin: a haemolytic protein purified from seeds of the Brazilian tree Enterolobium contortisiliquum. 1991 Toxicon pmid:1796477
Yara A et al. Cardiovascular effects of Acanthaster planci venom in the rat: possible involvement of PAF in its hypotensive effect. 1992 Toxicon pmid:1440631
Rees RS et al. Plasma components are required for platelet activation by the toxin of Loxosceles reclusa. 1988 Toxicon pmid:3245050
Freire-Maia L and de Matos IM Heparin or a PAF antagonist (BN-52021) prevents the acute pulmonary edema induced by Tityus serrulatus scorpion venom in the rat. 1993 Toxicon pmid:8266352
Tai H et al. TMVA, a snake C-type lectin-like protein from Trimeresurus mucrosquamatus venom, activates platelet via GPIb. 2004 Toxicon pmid:15501291
Melo RC et al. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. 2005 Traffic pmid:16138901
Guerrant RL et al. Diarrhea, demography and cell signaling: lessons from microbial toxins. 1997 Trans. Am. Clin. Climatol. Assoc. pmid:9108674
Shukla SD et al. Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity. 1989 Jul-Aug Transfusion pmid:2546298